Galmed Research and Development

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for liver and inflammatory diseases. The company's lead candidate, Aramchol, is a first-in-class Stearoyl-CoA Desaturase 1 (SCD1) inhibitor that has been evaluated in a Phase 3 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and fibrosis. Galmed is also advancing Amilo-5PR, a therapeutic peptide designed to inhibit the formation of serum amyloid A (SAA) fibrils for chronic inflammatory conditions. The company leverages its proprietary synthetic fatty acid/bile acid conjugate (FABAC) chemistry to target metabolic and fibrotic pathways. Headquartered in Israel, Galmed aims to address significant unmet needs in hepatology and gastroenterology.